Pd 1 Refractory Melanoma clinical trials

Explore recruiting pd 1 refractory melanoma clinical trials.

Recruiting pd 1 refractory melanoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pd 1 Refractory Melanoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizuma Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B

Spain, France, Greece, Poland, Italy, Hungary

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1/2 Open-label, Rolling-arm, Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYMAKER-U02): Substudy 02A

France, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Pd 1 Refractory Melanoma trials by city

Pd 1 Refractory Melanoma in Toronto Pd 1 Refractory Melanoma in Vancouver Pd 1 Refractory Melanoma in Montreal Pd 1 Refractory Melanoma in Calgary Pd 1 Refractory Melanoma in Edmonton Pd 1 Refractory Melanoma in Ottawa Pd 1 Refractory Melanoma in Winnipeg Pd 1 Refractory Melanoma in Quebec City Pd 1 Refractory Melanoma in Hamilton Pd 1 Refractory Melanoma in Kitchener Pd 1 Refractory Melanoma in London Pd 1 Refractory Melanoma in Halifax Pd 1 Refractory Melanoma in New York Pd 1 Refractory Melanoma in Los Angeles Pd 1 Refractory Melanoma in Chicago Pd 1 Refractory Melanoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease